- Investment Year
- 2010
- Sector
- Healthcare
- Geography
- North America - East
- Website
- www.verastem.com
Verastem
Biopharmaceutical company focused on discovering and developing novel drugs that selectively target cancer stem cells. Cancer stem cells are an underlying cause of tumor recurrence and metastasis. Verastem is translating breakthrough discoveries in cancer stem cell research into new medicines for the treatment of major cancers such as breast cancer. In January 2012, Verastem went public (NASDAQ: VSTM).
News
-
Thursday, July 14, 2011 (Source: BusinessWire)
Verastem raises $32M Series B Financing
-
Monday, June 13, 2011 (Source: Xconomy)
Former Genzyme CEO, Termeer, Joins Verastem Board
-
Monday, December 20, 2010 (Source: Wall Street Journal)
Scientists Target Tumors' Most Resilient Cells
-
Tuesday, November 16, 2010 (Source: xconomy)
Verastem Raises $16M to Fight Cancer Stem Cells
